Merck & Co., Inc. (VIE:MRK)

Market Cap	212.76B
Revenue (ttm)	54.75B
Net Income (ttm)	16.22B
Shares Out	n/a
EPS (ttm)	6.44
PE Ratio	13.11
Forward PE	11.12
Dividend	2.91 (3.38%)
Ex-Dividend Date	Sep 15, 2025

Volume	150
Average Volume	302
Open	86.30
Previous Close	87.20
Day's Range	86.10 - 87.20
52-Week Range	66.10 - 99.30
Beta	0.32
RSI	59.86
Earnings Date	Feb 3, 2026

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1891
• Employees: 75,000
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: MRK

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD